Novo Nordisk and OpenAI Launch Enterprise-Wide Partnership to Accelerate Obesity Drug Discovery
Novo Nordisk and OpenAI announced a partnership to deploy AI across R&D, manufacturing, and corporate functions, with pilot programs launching immediately and full integration targeted by end of 2026. The deal positions Novo to analyze complex datasets, identify new drug candidates, and compress R&D timelines as it fights to claw back market share from Eli Lilly. OpenAI will also provide AI literacy training to Novo's global workforce.